Afatinib

A cell permeable inhibitor of kinases that have been mutated, by a single base substitution, to become &#39analog sensitive&#39 (as), as compared to the wild type kinase inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src

A cell permeable inhibitor of kinases that have been mutated, by a single base substitution, to become &#39analog sensitive&#39 (as), as compared to the wild type kinase inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src

A cell permeable inhibitor of kinases that have been mutated, by a single base substitution, to become &#39analog sensitive&#39 (as), as compared to the wild type kinase inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4 / 6 inhibitor for the treatment of cancerForm:SolidIC50&amp: Target:CDK4 CDK6.

ACA-28 (compound 2a) is a potent ERK MAPK signaling modulator. ACA-28 selectively inhibits cancer cell growth by inducing apoptosis with ERK hyperactivationACA-28 inhibits cell growth of melanoma cells (SK-MEL-28) and normal melanocytes (NHEM), with

ACA-28 (compound 2a) is a potent ERK MAPK signaling modulator. ACA-28 selectively inhibits cancer cell growth by inducing apoptosis with ERK hyperactivationACA-28 inhibits cell growth of melanoma cells (SK-MEL-28) and normal melanocytes (NHEM), with

ACA-28 (compound 2a) is a potent ERK MAPK signaling modulator. ACA-28 selectively inhibits cancer cell growth by inducing apoptosis with ERK hyperactivationACA-28 inhibits cell growth of melanoma cells (SK-MEL-28) and normal melanocytes (NHEM), with